Tag: fell-as-much
-
BioMarin drug fails to show inattention, mood benefit in study
BioMarin Pharmaceutical Inc’s drug met a study’s main goal of reducing a toxic buildup of an amino acid in the blood of patients with a genetic disorder, but did not show enough benefit in related inattention and mood complications. BioMarin’s shares fell as much as 6 percent in early trading on Monday after the company…
-
Illicit drugs? How Brexit risks legal limbo for medicines
By Ben Hirschler LONDON (Reuters) – A British vote to leave the European Union would threaten some prescription medicines with regulatory limbo, posing a legal headache for drugmakers, according to lawyers and industry officials. The highly regulated pharmaceutical sector has more at stake than most from a so-called Brexit, prompting top manufacturers GlaxoSmithKline and AstraZeneca…